IP Library Granted Patent US 8,318,158
Granted Patent B2
US 8,318,158 · App. 13/271,783 · Granted Nov 27, 2012

Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same

Assignee: Curemark, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,158
App. No.
13/271,783
Granted
Nov 27, 2012
Kind
B2
Abstract

A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.

Claims (17)

1. A method for treating an alcohol or drug addicted individual exhibiting one or more symptoms of alcohol or drug addiction, wherein the one or more symptoms comprise a lack of protein digestion, a lack of nutrient absorption or a combination thereof; the method comprising:

(a) obtaining a fecal sample from the individual;

(b) measuring a level of chymotrypsin present in the fecal sample, wherein measuring comprises enzymatic photospectrometry analysis;

(c) comparing the level of chymotrypsin present in the fecal sample to a normal level of fecal chymotrypsin;

(d) administering a therapeutically effective amount of digestive enzymes to the individual if the measured fecal level of chymotrypsin is less than the normal level of fecal chymotrypsin; wherein the digestive enzymes comprise pancreatin, amylases, lipases, proteases or a combination thereof.

2. The method of claim 1 , wherein the proteases comprise chymotrypsin, trypsin, papain or a combination thereof.

3. The method of claim 1 , wherein the digestive enzymes are prepared using a technology comprising enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation or a combination thereof.

4. The method of claim 1 , wherein the digestive enzymes are administered orally via a dosage formulation comprising pills, tablets, capsules, microcapsules, mini-capsules, time released capsules, mini-tabs, sprinkles, or a combination thereof.

5. The method of claim 1 , wherein the amount of amylases ranges from 10,000 to 60,000 USP units/dose.

6. The method of claim 1 , wherein the amount of proteases ranges from 10,000 to 70,000 USP units/dose.

7. The method of claim 1 , wherein the amount of lipases ranges from 4,000 to 30,000 USP units/dose.

8. The method of claim 1 , wherein the amount of pancreatin ranges from 2,000 to 6,000 USP units/dose.

9. The method of claim 2 , wherein the amount of papain ranges from 3,000 to 10,000 USP units/dose.

10. The method of claim 2 , wherein the amount of trypsin ranges from 60 to 100 mg.

11. The method of claim 1 , wherein one of the one or more symptoms of the drug or alcohol addiction is ameliorated.

12. The method of claim 1 , wherein the total amount of the digestive enzymes ranges from about 4,000 to about 176,000 USP units/dose.

13. The method of claim 1 , wherein the normal level is 8.4 U/gram.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED ON REEL 028682 FRAME 0250. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 14, 2017
From: FALLON, JOAN M.
To: CUREMARK, LLC
Reel/Frame 041715/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2012
From: FALLON, JOAN M.
To: CUREMARK LLC
Reel/Frame 028682/0250 →
Continuity (3)
Continuation 12426794 · Apr 20, 2009
Provisional Application 61046026 · Apr 18, 2008
Related Publication 20120070504A1 · Mar 22, 2012